**Part 1 – Availability of frameworks/guidance documents/ guidelines to assess Digital Health Technologies (DHTs)**

| **Question** | **Answer** | **Reference (link)** |
| --- | --- | --- |
| Does your agency use a classification/grouping system or a taxonomy to assign specific DHTs to groups/levels/tiers within the framework (guidance document/guideline) to determine specific assessment or evidence requirements/standards? If yes, please provide a reference/link and/or attach a copy of any unpublished document. |  |  |
| Does your agency have any frameworks/guidance documents/guidelines that are used for assessing DHTs in general or for specific groups of DHTs? |  |  |
| If yes, please briefly specify what document type it is and for which groups of DHTs and purpose the document is intended to use. If unpublished, please attach a copy of the document with your responses. | Document type: |  |
| Types/groups/tiers of DHT addressed: |  |
| Purpose of the document: |  |
| Does your agency have any published or unpublished documents on evidence requirements or submission guidelines/templates for DHTs? If yes, please provide a link or attach with your responses. |  |  |
| If no such document already exists: is your organization currently developing or adapting a framework (guidance document/guideline) to be used for assessing DHTs? |  |  |
| If no DHT-specific framework/guidance document/guideline is available, what frameworks/guidance documents/guidelines does your agency consider appropriate for use in Health Technology Assessment (HTA) of DHTs? |  |  |

**Part 2 – Currents status of assessed DHTs**

| **Question** | **Answer** | **Reference (link)** |
| --- | --- | --- |
| Which digital health technologies have been evaluated by your agency so far?  Please provide us with a link where we can access these documents or send us the evaluation documents by e-mail. |  |  |
| Which digital health technologies are currently evaluated by your agency?  If possible, please provide us with a link to a listing of these technologies, or mention them directly. |  |  |

**Part 3 – Current gaps and weaknesses in assessing DHTs**

| **Question** | **Answer** | **Reference (link)** |
| --- | --- | --- |
| Do you see any gaps and weaknesses in the methods available to HTA bodies for assessing DHTs? |  |  |
| How does your agency approach these challenges of assessing DHT? |  |  |
| Which possible future approaches to overcome challenges in assessing DHTs do you suggest? |  |  |
| Do different methods should be used at each stage of the lifecycle of a DHT? While we concentrate on the health technology assessment stage, there may be different methods for market access or post-marketing surveillance. Please shortly explain. |  |  |
| Does your agency already use different methodological requirements for an HTA depending on the life cycle? |  |  |

**Part 4 – Request for an expert specialized in AI**

The Big Data Unit of the Andalusian public Progress and Health Foundation (Big Data-FPS) requests a nomination of an expert specialized in AI from your agency to participate in the following research.

Big Data-FPS *will circulate questionnaire/s (as part of an online Delphi approach) to HTA experts* *specialized in AI. Questions included will pertain to the development of validation methods for AI-based decision support systems. The inquiries will focus on guidance for the validation of these systems, optimization of algorithms, and strategies for estimating predictive abilities using real-world data.*

Not-applicable: ’The scope of the questions is outside of our agency remit’

Contact details: Name and e-mail address